论文部分内容阅读
目的探讨白三烯受体拮抗剂(孟鲁司特)治疗及预防婴幼儿喘息的疗效观察。方法选择2011年9月至2012年4月在我院住院喘息患儿144例,随机分为治疗组及对照组,综合治疗的基础上,治疗组同时给予孟鲁司特口服,连用4周并随访3个月,观察两组患儿临床疗效、治疗前后血清IgE水平,并于治疗结束后随访3个月,观察两组患儿喘息再发情况。结果两组患儿临床疗效、治疗前后血清IgE水平及出院后喘息复发率比较,差异均有显著性。结论孟鲁司特对于喘息患儿可明显改善其临床症状并预防喘息再发。
Objective To investigate the efficacy of leukotriene receptor antagonist (montelukast) in the treatment and prevention of wheezing in infants and young children. Methods 144 patients with respite in our hospital from September 2011 to April 2012 were randomly divided into treatment group and control group. On the basis of comprehensive treatment, the treatment group was given montelukast orally for 4 weeks The patients were followed up for 3 months. The clinical efficacy, serum IgE level before and after treatment in both groups were observed and followed up for 3 months after the treatment. The recurrent wheezing in both groups was observed. Results The clinical efficacy of two groups of children before and after treatment serum IgE levels and wheezing recurrence rate after discharge, the difference was significant. Conclusion Montelukast may improve the clinical symptoms and prevent recurrence of asthma in children with wheezing.